VIP Version: 1

• Research type

  Research Study

• Full title

  VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or metastatic pancreatic carcinoma.

• IRAS ID

  54528

• Contact name

  Gary Middleton

• Eudract number

  2010-021951-26

• ISRCTN Number

  74555382

• Research summary

  One of the standard treatments for advanced pancreatic cancer is gemcitabine chemotherapy used on its own, however new scientific findings suggest that the combination of gemcitabine with the tablet vandetanib may improve the outcome for patients diagnosed with pancreatic cancer. Vandetanib inhibits the blood supply to tumours and blocks two receptors on the surface of the cancer cells that are important in making the cells grow more rapidly and spread. In animal models the combination has much more effect on reducing the amount of cancer than in animals treated with gemcitabine alone. The primary purpose of this study is to establish if the combination of vandetanib and gemcitabine is more effective in treating a small number of patients with advanced pancreatic cancer than using gemcitabine on its own. The study will investigate if the combination of vandatinib and gemcitabine as compared with gemcitabine therapy prolongs the life of patients. We will also evaluate how vandetanib and gemcitabine as compared with gemcitabine therapy reduce the effects of pancreatic cancer and investigate the safety of the drugs. A further objective is to discover if blood from pancreatic cancer patients contains possible proteins, which predict if treatment with vandetanib in addition is better than using gemcitabine alone.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  11/LO/0097

• Date of REC Opinion

  15 Apr 2011

• REC opinion

  Further Information Favourable Opinion